---
title: "Quipt Home Medical projects steady margin expansion and operational growth in 2025"
date: "2025-02-12 00:40:48"
summary: "Earnings Call Insights: Quipt Home Medical (NASDAQ:QIPT) Q1 2025 Management View CEO Greg Crawford emphasized Quipt's strategic focus on respiratory care, which constitutes 77% of its product mix, aligning with macro trends such as an aging population and increasing prevalence of chronic respiratory conditions. The company operates 135 locations across..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: Quipt Home Medical (NASDAQ:[QIPT](https://seekingalpha.com/symbol/QIPT "Quipt Home Medical Corp.")) Q1 2025

### Management View

* CEO Greg Crawford emphasized Quipt's strategic focus on respiratory care, which constitutes 77% of its product mix, aligning with macro trends such as an aging population and increasing prevalence of chronic respiratory conditions. The company operates 135 locations across 26 states, serving 314,000 active patients.
* The company reported stable revenue of $61.4 million and adjusted EBITDA of $14 million, reflecting a sequential margin improvement to 22.8%. Crawford highlighted operational streamlining as a key factor in driving margin expansion.
* The CEO noted that GLP-1 medications have not impacted demand for sleep apnea products, with steady referral activity and replacement supply volumes.
* CFO Hardik Mehta stated, "Adjusted EBITDA sequentially increased by 4.5% from Q4 2024, in which the company reported adjusted EBITDA of $13.4 million at 21.8% margin." Mehta also mentioned the company's net leverage at 1.5x, enabling strategic investments.

### Outlook

* Management anticipates steady margin expansion throughout fiscal 2025, supported by operational efficiencies and cost structure optimization.
* The company aims to return to historical organic growth rates of 8% to 10% in calendar 2025, driven by initiatives in sales force expansion and technological enhancements.
* Regulatory stability is expected to provide operational confidence, with no significant headwinds projected in the near term.

### Financial Results

* Revenue for Q1 2025 was $61.4 million, flat compared to Q4 2024 but down 2% year-over-year. Adjusted EBITDA margin improved sequentially to 22.8%, reflecting operational improvements.
* Recurring revenue accounted for 77% of total revenue, demonstrating the stability of the business model.
* Net loss for Q1 2025 was $1.1 million, or $0.03 per diluted share, compared to $1.5 million, or $0.04 per diluted share, in Q1 2024.
* The company experienced headwinds from the discontinuation of the Medicare 75-25 blended rate, a disposable supply contract termination, and Medicare Advantage member withdrawals, with a quarterly impact of approximately $1.5 million.

### Q&A

* Richard Close, Canaccord Genuity: Questioned the impact of contract terminations and headwinds. CEO Greg Crawford explained that the incontinence supply contract termination would result in a $2.5 million headwind for calendar 2025, with stabilization expected in the second half.
* Doug Cooper, Beacon Securities: Inquired about resupply business growth. Crawford noted initiatives to improve catchment rates and compliance, aiming to drive growth in the resupply program.
* Bill Sutherland, The Benchmark Company: Asked about adjusted EBITDA margin targets. CFO Hardik Mehta stated that while 25% adjusted EBITDA margins are a long-term target, achieving it in the near future would require additional scale.

### Sentiment Analysis

* Analysts expressed concerns about headwinds from contract terminations and Medicare changes but acknowledged operational improvements. The tone was neutral to slightly positive.
* Management displayed confidence in addressing challenges, emphasizing stabilization and growth initiatives. They highlighted operational efficiencies and scalable strategies to drive performance.
* Compared to the previous quarter, management's tone was more optimistic about margin improvements and growth prospects, citing progress in operational initiatives.

### Quarter-over-Quarter Comparison

* Adjusted EBITDA improved sequentially from $13.4 million to $14 million, with margins increasing from 21.8% to 22.8%.
* Revenue remained flat sequentially but faced a year-over-year decline due to headwinds like the Medicare rate changes and contract terminations.
* Analysts' focus shifted from regulatory concerns in Q4 2024 to organic growth and margin improvement prospects in Q1 2025.
* Management's tone was steadier, reflecting confidence in operational discipline and demand trends.

### Risks and Concerns

* The discontinuation of the Medicare 75-25 blended rate and contract terminations are expected to impact revenue in fiscal 2025.
* Analysts raised concerns about the sustainability of margin improvements and the effectiveness of growth initiatives.
* Management highlighted mitigation strategies, including cost structure optimization and leveraging technology for operational efficiencies.

### Final Takeaway

Quipt Home Medical demonstrated operational improvements in Q1 2025, with adjusted EBITDA margin increasing sequentially despite revenue challenges. Management remains focused on returning to historical organic growth rates and achieving steady margin expansion through operational efficiencies and strategic initiatives. While headwinds persist, the company's commitment to scaling its respiratory care business and leveraging technological advancements positions it for long-term growth and shareholder value creation.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/QIPT/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4406487-quipt-home-medical-projects-steady-margin-expansion-and-operational-growth-in-2025)
